-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Evolving Standards of Care
-
Stereotactic Radiosurgery for Established Brain Metastases: Prospective Evidence
In the conclusion of this two-part series, Drs. Tomasik and Dziadziuszko highlight unresolved questions and future directions for integrating HA-PCI and SRS into practice for SCLC.
-
Targeting NRG1 Fusions: A Potential Role for Zenocutuzumab as a First-Line Therapeutic Option
Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.
-
National Report Shows Rising Lung Cancer Survival Rates but Gaps in Early Detection
The ALA’s 2025 State of Lung Cancer report highlights survival gains while revealing persistent disparities in diagnosis, treatment, and access to biomarker testing.
-
Modern Brain Radiotherapy in SCLC: Integrating Hippocampal Avoidance and Stereotactic Precision
Drs. Tomasik and Dziadziuszko discuss how the SCLC field is shifting toward brain-sparing techniques to maximize disease control, as well as cognitive preservation.
-
Updated Analysis Confirms Adding Pembrolizumab to Chemotherapy Improves Survival in Mesothelioma
Dr. Scott Laurie recently presented data from IND227 that showed the combination improved overall survival by 24% compared with chemotherapy alone.
-
IASLC Recommendations Define Core Standards for Molecular Tumor Boards
Lead author, Dr. Mihaela Aldea, discusses how the IASLC’s recently published consensus statement could strengthen new and established molecular tumor boards.
-
In Brief for November 19, 2025
The US FDA confirms the use of pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for solid tumor indications.
-
Patient Charts: How to Carefully Manage Patient Access to Health Information
Advocate Angus Pratt explores the pros and cons of patient access to electronic health records and discusses how the emergence of AI—with human oversight—could offer a way to navigate this complex issue.
-
Lessons from ECOG-ACRIN E4512: Could Limited Gains Lead to Positive Direction in Refining Adjuvant Therapy?
Discussant Dr. Jessica L. Lin said the results won’t change clinical practice after Dr. David Gerber reported no differences in OS or DFS.
-
Ivonescimab-Chemotherapy Combo Shows Promise as Post-TKI Option in EGFR-Mutant NSCLC
Dr. Jonathan W. Goldman reported that ivonescimab plus chemotherapy yielded a consistent PFS benefit across subgroups.